Aug. 5, 2026
— Jeff Ward, Lehigh Valley News Briefs
OraSure Technologies reported a second-quarter adjusted loss today of $13.8 million, or 20 cents per share.
Revenue in the quarter ended June 30 reached $30.6 million, topping the company’s forecast of $27 million to $30 million. Total revenue was down about 2% from the year-ago second quarter.
The Bethlehem-based maker of home-diagnostic tools and specimen-collection devices has been losing money for years. The stock has been a laggard since the flow of federal money stopped after the Covid-19 pandemic.
OraSure (NASDAQ:OSUR) is also burning cash. The company’s cash and cash equivalents at the end of the quarter were $160.6 million, down from $234.6 million a year ago.
The closing price today was $4.15. In the last 52 weeks, the shares have traded as low as $2.08 and as high as $4.58.
The adjusted earnings exclude items the company considers to be one-time or unusual. On a Generally Accepted Accounting Principles (GAAP) basis, OraSure made a profit of 9 cents per share in the second quarter.
Chief Executive Carrie Eglinton Manner will hold a conference call at 5 p.m. today. Eglinton’s goal is to sell more devices for patients to test themselves at home.
Will any Wall Street analysts show up? Zacks Investment Research, which compiles estimates of earnings and revenue, didn’t have any estimates on its website. That indicates a lack of interest in the company, now valued at about $286 million.
What is now OraSure has its roots in SolarCare (founded in 1988), which made sunscreen towelettes. The company’s products include InteliSwab, a test for Covid, and OraQuick, which detects HIV.
OraSure forecast third-quarter revenue today of $29.5 million to $32.5 million.
Lehigh Valley News Briefs 